Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Experimental Drugs and Mechanisms (TACTIC-E)

Trial Profile

mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Experimental Drugs and Mechanisms (TACTIC-E)

Status: Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 23 Mar 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ambrisentan (Primary) ; Dapagliflozin (Primary) ; EDP-1815 (Primary)
  • Indications COVID 2019 infections
  • Focus Therapeutic Use
  • Acronyms TACTIC-E
  • Most Recent Events

    • 18 Mar 2021 Planned End Date changed from 15 Jun 2021 to 15 Jun 2022.
    • 18 Mar 2021 Planned primary completion date changed from 15 Feb 2021 to 15 Feb 2022.
    • 07 Jan 2021 According to an Evelo Biosciences media release, expanding the international reach of EDP1815 in hospitalized patients with COVID-19, this trial recently received regulatory approval in Mexico, adding 7 hospitals to the trial.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top